About this Course
This course is a recorded (home study version) of the CE Finale Encore Webinars.
Upon completion of this knowledge based CE Activity, a pharmacist will be able to:
|· Describe how the FDA is currently funded and the implications for patient safety|
|· Describe how the nation’s inability to control concierge or internet prescription drug purchasing endangers patients|
|· Describe how the DSHEA act has placed patients in danger from adulterated or contaminated dietary supplements|
|· Describe how foreign inspections of manufacturing plants are separate and unequal and jeopardize patient health|
|· Describe how relying on the Interstate Commerce Act allows pharmaceutical companies to circumvent research subject protections overseas|
|· Describe how to remedy or ameliorate these issues|
Release and Expiration Dates
Released: December 20, 2021
Expires: December 17, 2024
1.0 hours of CE
|The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-21-052-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.
C. Michael White, PharmD, FCCP, FCP
BOT Distinguished Professor
Chair of Pharmacy Practice
University of Connecticut School of Pharmacy
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
- C. Michael White has no relationships with ineligible companies
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
1. Why did the FDA start applying user fees to manufacturers and what percentage of overall FDA funding comes from the companies they oversee?
A. Because of the HIV/AIDS crisis – 65% of funds come from manufacturer fees
B. Because of the HIV/AIDS crisis – 45% of funds come from manufacturer fees
C. Because of the ebola crises – 45% of funds come from manufacturer fees
2. What is the primary way that people are accessing counterfeit drugs?
A. Through the local community or retail pharmacy
B. Through a licensed domestic mail order pharmacy
C. Through an unlicensed foreign mail order pharmacy
3. Which of the following is a validated way to assure a dietary supplement does not have excessive microbial or heavy metal contamination and has the ingredient in the tablets/capsules advertised on the label?
A. Selecting a product with USP certification
B. Looking for Better Homes and Gardens Certification
C. Buying the most expensive product
4. What occurred simultaneously with the increase in foreign manufacturing site FDA inspections that attenuates the safety benefits to the US patient?
A. A reduction in domestic inspections
B. A lower caliber of foreign inspections
C. A reduction in the FDA inspector workforce
5. What are the risks associated with drug trials shifting overseas?
A. Ethical violations or subject harm will become more prevalent
B. The FDA will have insufficient dataset about risk/benefit balance
C. American jobs will be lost in part due to an unequal playing field
D. All of the above